61 related articles for article (PubMed ID: 277247)
21. Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.
Urtasun RC; Band P; Chapman JD; Rabin HR; Wilson AF; Fryer CG
Radiology; 1977 Mar; 122(3):801-4. PubMed ID: 841074
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma.
Dische S
Radiother Oncol; 1987 Oct; 10(2):111-6. PubMed ID: 2447612
[TBL] [Abstract][Full Text] [Related]
23. A preliminary clinical study of the use of mycophenolic acid as a radiosensitizer.
Bates T
Eur J Cancer (1965); 1977; 13(4-5):475-7. PubMed ID: 326560
[No Abstract] [Full Text] [Related]
24. Further investigations of the effects of the hypoxic-cell radiosensitizer, Ro-07-0582, on local control of a mouse tumour.
Sheldon PW; Hill SA
Br J Cancer; 1977 Aug; 36(2):198-205. PubMed ID: 911657
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxicity and radiosensitization in mouse and man.
Denekamp J
Br J Radiol; 1978 Aug; 51(608):636-7. PubMed ID: 678761
[No Abstract] [Full Text] [Related]
26. Lung metastasis suppression of the bifunctional new radiosensitizer KIN-806.
Inomata T; Ogawa Y; Itoh S; Kariya S; Hamada N; Nishioka A; Yoshida S; Nagasawa H; Hori H; Inayama S
Int J Mol Med; 1999 Sep; 4(3):257-60. PubMed ID: 10425275
[TBL] [Abstract][Full Text] [Related]
27. Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.
Gray AJ; Dische S; Adams GE; Flockhart IR; Foster JL
Clin Radiol; 1976 Apr; 27(2):151-7. PubMed ID: 776493
[TBL] [Abstract][Full Text] [Related]
28. Interstitial misonidazole. A preliminary report on a new perspective in clinical radiation sensitization and hypoxic cell chemotherapy.
Sealy R; Korrubel J; Cridland S; Blekkenhorst G
Cancer; 1984 Oct; 54(8):1535-40. PubMed ID: 6478394
[TBL] [Abstract][Full Text] [Related]
29. Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring.
Workman P; Wiltshire CR; Plowman PN; Bleehen NM
Br J Cancer; 1978 Dec; 38(6):709-18. PubMed ID: 743488
[TBL] [Abstract][Full Text] [Related]
30. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.
Dische S; Saunders MI; Lee ME; Adams GE; Flockhart IR
Br J Cancer; 1977 May; 35(5):567-79. PubMed ID: 861146
[TBL] [Abstract][Full Text] [Related]
31. Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography.
Workman P; Little CJ; Marten TR; Dale AD; Ruane RJ; Flockhart IR; Bleehen NM
J Chromatogr; 1978 May; 145(3):507-12. PubMed ID: 659541
[No Abstract] [Full Text] [Related]
32. Thermal enhancement of radiation response: a growth delay study on superficial human tumour metastases.
Tait DM; Carnochan P
Radiother Oncol; 1987 Jul; 9(3):231-40. PubMed ID: 3306809
[TBL] [Abstract][Full Text] [Related]
33. Change in volume of irradiated human metastases. Investigation of repair of sublethal damage and tumour repopulation.
Malaise EP; Charbit A; Chavaudra N; Combes PF; Douchez J; Tubiana M
Br J Cancer; 1972 Feb; 26(1):43-52. PubMed ID: 5014754
[TBL] [Abstract][Full Text] [Related]
34. Serum concentration measurements in man of the radiosensitizer Ro-07-0582: some preliminary results.
Foster JL; Flockhart IR; Dische S; Gray A; Lenox-Smith I; Smithen CE
Br J Cancer; 1975 Jun; 31(6):679-83. PubMed ID: 1174445
[No Abstract] [Full Text] [Related]
35. Radiation-induced oxidative denitration of 2-nitroimidazoles in aqueous solution.
Ide H; Ohkubo O; Sakamoto A; Nishimoto S; Wada T; Kagiya T
J Radiat Res; 1984 Sep; 25(3):246-50. PubMed ID: 6512746
[No Abstract] [Full Text] [Related]
36. The effect of bioreduction on the oncogenicity of nitroimidazoles.
Hall EJ; Hei TK
Biochem Pharmacol; 1986 Jan; 35(1):93-4. PubMed ID: 3940531
[No Abstract] [Full Text] [Related]
37. Tumor growth delay studies in patients with multiple metastatic nodules: practical difficulties.
Urtasun RC; Band P; Ferri H
Int J Radiat Oncol Biol Phys; 1980 Jul; 6(7):875-7. PubMed ID: 7204124
[No Abstract] [Full Text] [Related]
38. Loss of hearing after misonidazole.
Abratt RP; Blackburn JD
Br J Radiol; 1980 Dec; 53(636):1208. PubMed ID: 7437740
[No Abstract] [Full Text] [Related]
39. Curing Metastatic Disease With Ablative Radiation Therapy: Separating Truth From Wish.
Kamran SC; Zietman AL
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):433-436. PubMed ID: 32531389
[No Abstract] [Full Text] [Related]
40. Curing Metastatic Disease with Radiation Therapy: Myth or Reality?-Arguing for Reality.
Rahimi A; Timmerman R
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):429-432. PubMed ID: 32531388
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
